26677 MBINBIO@EC2607A.C
- 0.275
- -0.015-5.17%
Cinda Biotech (1801.HK): Outstanding efficacy of PD-1 & IL2α at ESMO & WCLC
China Galaxy Securities Starts Innovent Biologics at Add With HK$55.92 Price Target
Cinda Biotech (01801.HK): Independent research and development has made a breakthrough in commercialization in four major fields
haitong int'l: Maintains the "outperform" rating on innovent bio (01801), with the target price raised to HKD 67.8.
Cinda Biotech (1801.HK): Steady implementation of business strategies and continuous improvement of operational efficiency
Cinda Biotech (1801.HK): Excellent sales performance in the first half of the year 2024-26E revenue will grow rapidly
Cinda Biotech (1801.HK): Strong Revenue Growth Accelerates Innovation Pipeline
INNOVENT BIOLOGICS(1801.HK):2025 EBITDA BREAKEVEN GOAL UNCHANGED
Bocom Int'l: Raised target price of Innovent Bio to HKD 60 and raised revenue forecast for 2024-2026.
Bank of America Securities: Reaffirms a 'buy' rating for Innovent Bio (01801), with the target price raised to 54.1 Hong Kong dollars.
Cinda Biotech (1801.HK): 1H24 exceeds expectations 2H24-2025 intensive price increases for commercialization and clinical catalysts
Nomura Adjusts Innovent Biologics' Price Target to HK$58.09 From HK$55.87, Keeps at Buy
Cinda Biotech (1801.HK): Excellent R&D and sales performance surpassed expectations, and business quality improved significantly
Major Bank Rating | JPMorgan: Raises Innovent Bio's target price to HKD 55, raises sales forecast for fiscal years 2024 to 2026.
UBS Group: Maintains a 'buy' rating on Innovent Bio (01801), with a target price raised to HKD 60.7.
Cinda Biotech (1801.HK): 1H24 product revenue growth rate is impressive, net loss narrows better than expected
Cinda Biotech (1801.HK): Rapid revenue growth, WCLC/ESMO data update is worth looking forward to
Cinda Biotech (01801.HK): The approved dosage of Mashidu peptides is worth looking forward to, and the significant potential of PD-1/IL-2 antibodies is beginning to show
Cinda Biotech (01801.HK): Scarce platform-based innovative drug enterprise pipeline has entered an intensive cashout period
CICC: Maintains 'Outperform' rating for Innovent Bio (01801), target price raised to HKD 55.5.